Nanobiotix S.A. (NANO) Earnings Call Transcripts

Nanobiotix S.A.'s Latest Earnings Call - Q4 FY2025

In the full year 2025 earnings call, Nanobiotix S.A. reported a significant revenue turnaround, recognizing EUR 32.6 million compared to a negative EUR 7.2 million in 2024, largely due to a one-time accounting impact from a licensing agreement with Johnson & Johnson (J&J). The company also highlighted a strategic shift in its collaboration with J&J, which has improved its financial outlook and cash visibility into 2028. Management maintained a positive outlook on the development of its lead product, NBTXR3, with multiple upcoming clinical trial readouts expected to drive future value.

Reported metrics

Guidance from management

Nanobiotix anticipates continued progress in clinical trials with multiple data readouts expected in 2026 and 2027, particularly for NBTXR3. The company has not raised or lowered its guidance but maintains a positive outlook on cash visibility into 2028.

What management said

Thank you for the question. Well, first of all, we can talk for our partner. J&J now is running the CONVERGE trial and has the license on the product. So that will be their decision. And I think it's a bit early to talk about that. That may be a question we could ask when we see the data coming from the Phase II. But if the data are excellent, everything is open. But again, that will be a J&J's decision to move that ...

We are pushing both because we think building our internal pipeline will go through have a first proof of concept of this product into human, and that's what the team is working on, not only by manufacturing the product and starting pre-IND studies, but also designing the first proof of concept we want to bring to life. And if we think about it, as soon as we have established the safety and feasibility of this produc...

What analysts pressed on

Analysts expressed concerns regarding the potential for J&J to prioritize other indications beyond head and neck and lung cancer. There were also questions about the sustainability of the current cash burn rate and the implications of trial results on future Phase III decisions.

Main topics on the call

• Revenue Turnaround — Nanobiotix reported revenue of EUR 32.6 million for 2025, a significant increase from negative EUR 7.2 million in 2024, primarily due to a one-time accounting effect from the licensing agreement with J&J. Bart Van Rhijn ...
• Strategic Partnership with J&J — The partnership with J&J has been restructured to remove most funding obligations for the NANORAY-312 study, enhancing Nanobiotix's financial flexibility. Management emphasized that this partnership is crucial for access...
• Clinical Trial Developments — Nanobiotix is advancing multiple trials for NBTXR3, including a Phase III trial in head and neck cancer and a Phase II trial in lung cancer. The first readout for the Phase III trial is expected in the first half of 2027...
• Curadigm Platform Progress — The Curadigm platform is progressing with preclinical studies and patent filings, aiming to enhance drug delivery and reduce liver toxicity. Management indicated that they expect to file for an IND soon, which could open...

Read the full Nanobiotix S.A. transcript (Q4 FY2025) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 14 Nanobiotix S.A. earnings call transcripts on record, spanning April 25, 2023 to April 1, 2026. Based on this history, Nanobiotix S.A. reports quarterly. The most recent call on file is dated April 1, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

NANO

Exchange

ENXTPA

Country

FR

Sector

Health Care

Industry

Biotechnology

Calls on record

14

First call

April 25, 2023

Most recent

April 1, 2026

Reporting cadence

quarterly